Abstract:

Hyperprogressive disease is a new pattern of progression recently described in patients with cancer treated with immunotherapeutics, which are represented by programmed cell death-1 and programmed cell death ligand-1 (PD-1/PD-L1) inhibitors. Hyperprogressive manifests as after anti-PD-1/PD-L1 immunotherapy, the patient's condition worsens and tumor grows faster. At present, on account of its unclear mechanism and a lack of effective treatment methods, the incidence of hyperprogressive is high and the prognosis of hyperprogressive patients is poor.

Key words:Immunotherapy,Hyperprogression,PD-1/PD-L1